Want to see FR:ALMDT full AI Analyst Report?

Median Technologies (ALMDT) Price & Analysis

20 Followers

ALMDT Stock Chart & Stats

€4.57

€0.43(9.87%)

At close: Jan 09 4:00 PM EST

€4.57

€0.43(9.87%)

Day’s Range― - ―

52-Week Range€1.68 - €7.27

Previous CloseN/A

Volume91.16K

Average Volume (3M)465.96K

Market Cap

€241.89M

Enterprise Value€196.06M

Total Cash (Recent Filing)€18.41M

Total Debt (Recent Filing)€21.76M

Price to Earnings (P/E)―

Beta0.52

Next Earnings

Oct 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.15

Shares Outstanding48,659,187

10 Day Avg. Volume398,206

30 Day Avg. Volume465,957

Financial Highlights & Ratios

PEG Ratio0.16

Price to Book (P/B)-4.95

Price to Sales (P/S)7.45

P/FCF Ratio-9.58

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.48

Revenue Forecast (FY)€26.53M

Bulls Say, Bears Say

Bulls Say

Specialized AI Imaging Platform For Clinical TrialsMedian's focused product set—image-based biomarkers and AI for oncology and clinical trials—represents a durable competitive niche. Serving trial imaging needs requires domain expertise and regulatory alignment, creating higher switching costs and long sales cycles that favor incumbents with validated analytics.

Improving Revenue Growth TrajectoryA +21.5% revenue increase in 2025 shows meaningful commercial traction in a specialized market. Consistent top-line growth supports scale economics potential and demonstrates client adoption of services and software, providing a foundation to improve unit economics if cost structure is addressed.

Diversified Revenue Model Tied To Biopharma DemandMix of contracted trial services, software licensing, and collaborations aligns revenue with structural biopharma trends. This diversification helps smooth project cadence and creates multiple routes to scale: professional services drive near-term bookings while software/partnerships offer higher-margin, repeatable revenue over time.

Bears Say

Persistent Negative Operating Cash FlowSustained negative operating cash flow signals the business requires external funding to sustain operations. Over time this increases financing and dilution risk, limits ability to invest in product development or sales expansion, and constrains resilience against slower contract cycles.

Negative Shareholders' Equity Weakens Balance SheetNegative equity across multiple years materially impairs financial flexibility and raises solvency concerns. This structural weakness restricts borrowing capacity, raises counterparty and customer risk perceptions, and makes it harder to absorb setbacks or invest for long-term growth without dilutive financing.

Deep Unprofitability And Negative Gross ProfitNegative gross profit indicates structural unit-economics issues—costs or pricing that destroy value at the product or service level. Even with revenue growth, loss-making core operations make sustainable profitability uncertain and lengthen the path to positive free cash flow.

Median Technologies News

Stifel Nicolaus Recommends ‘Buy’ for Median Technologies Amid Strategic Financial Moves and Growth Potential

In a report released today, from Stifel Nicolaus reiterated a Buy rating on Median Technologies, with a price...

9M ago

ALMDT FAQ

What was Median Technologies’s price range in the past 12 months?

Median Technologies lowest stock price was €1.68 and its highest was €7.27 in the past 12 months.

What is Median Technologies’s market cap?

Median Technologies’s market cap is €241.89M.

When is Median Technologies’s upcoming earnings report date?

Median Technologies’s upcoming earnings report date is Oct 15, 2026 which is in 101 days.

How were Median Technologies’s earnings last quarter?

Median Technologies released its earnings results on Apr 23, 2026. The company reported -€0.677 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.677.

Is Median Technologies overvalued?

According to Wall Street analysts Median Technologies’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Median Technologies pay dividends?

Median Technologies does not currently pay dividends.

What is Median Technologies’s EPS estimate?

Median Technologies’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Median Technologies have?

Median Technologies has 48,659,187 shares outstanding.

What happened to Median Technologies’s price movement after its last earnings report?

Median Technologies reported an EPS of -€0.677 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.957%.

Which hedge fund is a major shareholder of Median Technologies?

Currently, no hedge funds are holding shares in FR:ALMDT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Median Technologies

Headquartered in Valbonne, France, Median Technologies S.A. was established in 2002. This company specializes in developing and commercializing advanced software and platforms designed for medical image analysis. Its reach extends globally, serving markets in France, the United States, Canada, the United Kingdom, China, and beyond. Among its key offerings is iBiops, an innovative, AI-powered software classified as a medical device. This solution comprehensively integrates and optimizes the entire medical imaging workflow. Additionally, Median Technologies provides iSee, a service dedicated to image analysis specifically for clinical trials. Furthermore, the company delivers extensive imaging contract research organization (CRO) services. These encompass a wide range of activities, from study initiation and the management of both image and clinical data, to scientific advisory, independent reviews, image data processing, site support, and final study close-out. Solidifying its commitment to research, Median Technologies maintains a collaborative agreement with the University of California.